Dependent Care Expansion Boosts Survival in AYA Patients With Cancer


Research showed a survival improvement in adolescent and young adult cancer survival after the Dependent Care Expansion allowed patients to be on their parents’ insurance until the age of 26.

Adolescent and young adult (AYA) patients with cancer tend to have the largest proportion of individuals who are uninsured, though the Affordable Care Act’s Dependent Care Expansion (DCE) is help bridging that gap — and may even lead to improved outcomes, explained Dr. Susan Parsons, medical director of the Reid R. Sacco AYA Cancer Program at Tufts Medical Center in Boston and professor of medicine and pediatrics at Tufts University School of Medicine.

The DCE allows eligible young adults to stay on their parents’ insurance plan until the age of 26. Parsons cited recent research published in the journal The Oncologist showing two-year survival significantly improved for patients between the ages of 19 and 23 after the DEC was passed.

“So that was a huge impact to get them insured, but to see that translate to better cancer outcomes was really impressive,” Parsons said.

READ MORE:The ‘Toxicity of Cancer’ Includes Lifetime Economic, Non-Financial Costs in AYAs


I think that there are a couple of federal programs that parents may need to be aware of, particularly for young adults, and that I think the one that is the most impactful in terms of impact on survival is the Dependent Care Expansion (DCE) under the Affordable Care Act.

DCE allowed patients to remain on their parents’ health insurance until the age of 26, which was hugely impactful. And I was at a conference last week and (Dr. Michael) Roth from (The University of Texas) MD Anderson (Cancer Center) showed some incredible slides that that patients who were insured under the DCE actually had better survival. … That was incredible to me. I mean, I had long been aware of that provision, I was very happy about that, because AYAs historically had the largest proportion of uninsured among any cancer group. So that was a huge impact to get them insured, but to see that translate to better cancer outcomes was really impressive.

So, parents need to know about that so that they don't make the mistake of dropping their child's coverage for that very vulnerable period of transition from late adolescence to early young adulthood which is fraught with all sorts of important transitions.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Jessica McDade, B.S.N., RN, OCN, in an interview with CURE
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE
Related Content